^
Association details:
| Biomarker: | RET C634* |
|---|---|
| Cancer: | Thyroid Gland Medullary Carcinoma |
| Drug: | Gavreto (pralsetinib) (RET inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Results from the registrational phase I/II ARROW trial of pralsetinib (BLU-667) in patients (pts) with advanced RET mutation-positive medullary thyroid cancer (RET+ MTC)
Published date:
11/17/2020
Excerpt:
We report efficacy for response-evaluable pts (REP) with RET+ MTC and safety for all pts who initiated pralsetinib...In 79 REP with RET+ MTC (mutation: 61% M918T, 28% C634X, 4% V804X, 8% other), ORR was 65% (95% CI 53–75; n=51/79, 5% complete response [CR]; 59% partial response [PR; 1 pending confirmation]).Pralsetinib demonstrated potent and durable clinical activity in RET+ MTC.
Trial ID:
